Innovación en primera línea de tratamiento del sarcoma de partes blandas

27 / 34

© 2017 Eli Lilly and Tap WD et al. Lancet 2016;388:488-97 (updated 388:464)
Time (Months)
Olaratumb+Doxorubicin
Independent Review
Assessment
Olaratumab +
Dox Dox
Patients/Events 66/37 67/34
Median, months
(95% CI)
8.2
(5.5, 9.8)
4.4
(3.1, 7.4)
HR (95% CI) 0.67 (0.40, 1.12)
Stratified p-value .1208
Investigator
Assessment
Olaratumab +
Dox Dox
Patients/Events 66/55 67/48
Median, months
(95% CI)
6.6
(4.1, 8.3)
4.1
(2.8, 5.4)
HR (95% CI) 0.67 (0.44, 1.02)
Stratified p-value .0615a
aMet predefined criterion of α=0.20
PFS